DOCSLIB.ORG

Fiscal Year 2006

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fiscal Year 2006 NATIONAL INSTITUTES OF HEALTH National Library of Medicine Programs and Services Fiscal Year 2006 U.S. Department of Health and Human Services Public Health Service Bethesda, Maryland i National Library of Medicine Catalog in Publication Z National Library of Medicine (U.S.) 675.M4 National Library of Medicine programs and services.— U56an 1977- .—Bethesda, Md. : The Library, [1978- v.: ill., ports. Report covers fiscal year. Continues: National Library of Medicine (U.S.). Programs and Services. Vols. For 1977-78 issued as DHEW publication; no. (NIH) 78-256, etc.; for 1979-80 as NIH publication; no. 80-256, etc. Vols. 1981 – present Available from the National Technical Information Service, Springfield, Va. ISSN 0163-4569 = National Library of Medicine programs and services. 1. Information Services – United States – periodicals 2. Libraries, Medical – United States – periodicals I. Title II. Series: DHEW publication; no. 80-256, etc. DISCRIMINATION PROHIBITED: Under provisions of applicable public laws enacted by Congress since 1964, no person in the United States shall, on the ground of race, color, national origin, sex, or handicap, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance. In addition, Executive Order 11141 prohibits discrimination on the basis of age by contractors and subcontractors in the performance of Federal contracts. Therefore, the National Library of Medicine must be operated in compliance with these laws and executive order. ii CONTENTS Preface ............................................................................................................................................................. v Office of Health Information Programs Development .................................................................................... 1 Planning and Analysis....................................................................................................................... 1 Outreach and Consumer Health ........................................................................................................ 2 International Programs ...................................................................................................................... 4 Library Operations .......................................................................................................................................... 6 Program Planning and Management ................................................................................................. 6 Collection Development and Management ....................................................................................... 7 Vocabulary Development and Standards .......................................................................................... 8 Bibliographic Control ..................................................................................................................... 10 Information Products ...................................................................................................................... 11 Direct User Services ....................................................................................................................... 13 Outreach .......................................................................................................................................... 14 Specialized Information Services ................................................................................................................. 22 Toxicology and Environmental Health Resources .......................................................................... 22 AIDS Information Services ............................................................................................................. 23 Evaluation Activities ....................................................................................................................... 23 Outreach Initiatives ......................................................................................................................... 24 Research and Development Initiatives ............................................................................................ 25 Lister Hill Center .......................................................................................................................................... 26 Biomedical Imaging ........................................................................................................................ 26 Document Imaging Analysis and Understanding............................................................................ 29 Information Systems ....................................................................................................................... 30 Infrastructure Research ................................................................................................................... 33 Language and Knowledge Processing ............................................................................................ 35 Multimedia Visualization ................................................................................................................ 39 Training Opportunities .................................................................................................................... 40 National Center for Biotechnology Information .......................................................................................... 41 GenBank: The NIH Sequence Database ......................................................................................... 41 Genome Resources ......................................................................................................................... 42 Genome-Wide Association Studies ................................................................................................ 45 Other Specialized Databases and Tools .......................................................................................... 45 PubChem and Protein Data ............................................................................................................. 46 Literature Databases........................................................................................................................ 47 The BLAST Suite of Sequence Comparison Programs ................................................................. 48 Database Access ............................................................................................................................. 48 Research .......................................................................................................................................... 49 Outreach and Education .................................................................................................................. 49 Biotechnology Information in the Future ........................................................................................ 51 Extramural Programs ................................................................................................................................... 52 Success Rates .................................................................................................................................. 52 Research Support for Biomedical Informatics and Bioinformatics ................................................ 53 Resource Grants .............................................................................................................................. 55 Training and Fellowships ................................................................................................................ 56 Pan-NIH Projects ............................................................................................................................ 58 EP Operating Units ......................................................................................................................... 59 Office of Computer and Communications Systems ..................................................................................... 64 Executive Summary ........................................................................................................................ 64 Business Continuity and Disaster Recovery ................................................................................... 64 iii Consumer Health ............................................................................................................................ 64 IT Security ...................................................................................................................................... 65 Professional Health Information ..................................................................................................... 66 Network and Systems Support ........................................................................................................ 67 Desktop Support ............................................................................................................................. 68 Outreach .......................................................................................................................................... 68 Research and Development Initiatives ............................................................................................ 69 NLM Web Support ........................................................................................................................
Load more

Recommended publications
  • 24/05/2009 the Challenges of Advocating for Open Access
    Date submitted: 24/05/2009 The challenges of advocating for open access through institutional repository building: experiences from Makerere uniVersity, Uganda Miriam Kakai Digitization/Microfilming Section Makerere University Library P.O. Box 7062, Kampala, Uganda E-Mails: [email protected] [email protected] Meeting: 105. Library Theory and Research WORLD LIBRARY AND INFORMATION CONGRESS: 75TH IFLA GENERAL CONFERENCE AND COUNCIL 23-27 August 2009, Milan, Italy http://www.ifla.org/annual-conference/ifla75/index.htm Abstract: This paper was perceived as a result of the slow response in populating an institutional repository at Makerere University, launched in 2006 under the umbrella name “Uganda Scholarly Digital Library (USDL)”. Having heard of the adage that goes “build it and they will come”, the calamities of being disappointed by waiting to see the repository growing at the researchers will were avoided. In response to this, awareness campaigns were launched, efforts to sensitise and collect content at unit and individual level were undertaken, and publicity done alongside the regular information literacy sessions conducted by Makerere University Library. To-date, the publications archived in USDL are less than 1,000 items. Given that USDL was initiated to ease accessibility to publications that were difficult to come by, open access was advocated for. However, there are challenges experienced so far and these include the status of institutional copyright policies, absence of tools to enforce or implement mandatory archiving, and the submission of electronic theses and dissertations, varying publisher copyright policies; difficulties in obtaining author versions of publications, doubts about the quality of open access research, plagiarism fears, and technical limitations.
    [Show full text]
  • Clinical Protocol P-321-202
    Clinical Protocol P-321-202 Project Number P-1003-I101 Compound Number/ Name P-321 Ophthalmic Solution Protocol Number P-321-202 Protocol Title Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease Assessing Safety and Efficacy Over 28 Days Sponsor Parion Sciences, Inc. 2800 Meridian Parkway Suite 195 Durham, NC 27713 Medical Monitor Authors Issue Date Original: Version 1.0 released 29 April 2016 Amendment 1.0: Version 2.0 Released 10 February 2017 Sponsor Signature and Date _____________________________________________ The information in this document is confidential and is provided to you as an investigator or consultant for review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written authorization from Parion Sciences. Parion Sciences, Inc. P-321 Ophthalmic Solution Protocol P-321-202 Amendment 01 PARION SCIENCES, INC. Clinical Protocol P-321-202 Investigator Signature Page Project Number P-1003-I101 Compound Number/ Name P-321 Ophthalmic Solution Protocol Number P-321-202 Protocol Title Randomized, Double-Masked, Parallel Group Study of P - 321 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease Assessing Safety and Efficacy Over 28 Days Sponsor Parion Sciences, Inc. 2800 Meridian Parkway Suite 195 Durham, NC 27713 Issue Date Original: Version 1.0 released 29 April 2016 Amendment 1.0: Version 2.0: Released 10 February 2017 I have reviewed and understand this protocol and all amendments associated with it.
    [Show full text]
  • Don't Lose Sight of Cataract
    Don’t lose sight of Cataracts Information for people at risk What is cataract? 1 When the lens of your eye gets cloudy, it is called a cataract. It can cause vision loss in one or both eyes. It cannot spread from one eye to the other. What causes a cataract? 2 The lenses of the eyes are made mostly of water and protein. As we age, some of this protein may clump together and cloud the lenses of our eyes. Over time, this “cloud” may grow and cover more of the lens. This makes it harder to see. Smoking, alcohol use, diabetes, and prolonged exposure to the sun can also cause cataract. When are you most likely to have a cataract? 3 Older people mostly get cataracts. But people in their 40s and 50s may get them, especially if the eye has been injured. The risk of having a cataract increases after age 60, and by age 80, more than half of all Americans will have a cataract or will have had cataract surgery. Normal vision. What are the symptoms of a cataract? A scene as it might be viewed by a 4 When you first get a cataract, you may not notice much person with a cataract. change. Your vision may become blurry, as if looking through a foggy window. Or colors may not appear as bright as they once did. As the “cloud” over the lens of your eye grows, it may be harder for you to read. You may also see more glare from a lamp or car headlights at night.
    [Show full text]
  • National Institutes of Health
    Trusted Health Information from the National Institutes of Health ® MedlineNIHFall 2011 Plusthe magazine Plus, in this issue! • Controlling High Blood Pressure Young adults at risk • Managing Asthma Actress Turning discovery Debra Winger into health “Everyone is touched • Millions by addiction...” Untreated Get tested for peripheral Speaking out for artery disease Drug Abuse Education A publication of the NATIONAL INSTITUTES OF HEALTH and the FRIE NDS of the NATIONAL LIBRARY OF MEDICINE FRIENDS OF THE NATIONAL LIBRARY OF MEDICINE 2011 Awards Gala Celebrating Leadership in Health and Medicine & 175th Anniversary of the National Library of Medicine Thursday, November 3, 2011 6:30 – 9:30 PM Great Hall, Jefferson Building Library of Congress Photo: NLM Photo: Washington, DC Donald West King, M.D. FNLM Chairman Photo: LibraryPhoto: of Congress t is an honor and pleasure each year for the Friends to hold an Awards Gala to celebrate the For more information advancements made in public health, medicine, and health communications, along with the on how to attend, visit individuals and organizations who are dedicated to this cause. The 2011 Annual Awards Gala on November 3 will bring together representatives from the public, professional, and business sectors in www.fnlm.org or call Ihealth care to show their support for the Library—this year celebrating its 175th anniversary. 202-679-9930. For their achievements and support of the advancement of health, five recipients will be honored: n Distinguished Medical Informatics Award Larry Ellison, Founder and CEO, Oracle n Paul G. Rogers Health Communications Award Mehmet Oz, MD, and Michael Roizen, MD, co-authors, YOU: The Owner’s Manual Let Us Hear From You! n Distinguished Medical Science Award Purnell W.
    [Show full text]
  • Incorporating Sex As Biologic Variable to Advance Health
    Connors-BRI Symposium: Incorporating Sex as Biologic Variable to Advance Health Monday, May 24th, 2021 3:00 - 5:00PM ET || Virtual AGENDA Welcoming Remarks Hadine Joffe, MD, MSc 3:00PM Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health Vice Chair for Research, Department of Psychiatry Brigham and Women’s Hospital / Harvard Medical School INTRODUCTION BY: Keynote Address 3:05PM Kathryn Rexrode, MD, MPH Chief, Division of Women’s Health, Department of Medicine Associate Professor of Medicine Brigham and Women’s Hospital / Harvard Medical School KEYNOTE: Why Studying Sex and Gender is Square One Janine Austin Clayton, MD Associate Director for Research on Women’s Health Director of the Office of Research on Women’s Health National Institutes of Health Featured Short Talks INTRODUCTION BY: 3:45PM Laura M. Holsen, MS, PhD Associate Psychologist Assistant Professor of Psychiatry Brigham and Women’s Hospital / Harvard Medical School SHORT TALKS BY: Sexual dimorphism in genetic associations of testosterone and sex-hormone binding globulin with coronary heart disease Jie Hu, MD, PhD, Brigham and Women’s Hospital Network medicine approaches reveal sex differences in lung cancer gene regulation Camila Lopes-Ramos, PhD, Harvard TH Chan School of Public Health Plasma glycated CD59 (pGCD59) accurately predicts early gestational diabetes (GDM) Michelle Toth-Castillo, BSc, Brigham and Women’s Hospital INTRODUCTION BY: 4:20PM Lightning Talks P. Emanuela Voinescu, MD, PhD Assistant Professor of Neurology Brigham and Women’s Hospital / Harvard Medical School Dawn L. DeMeo, MD, MPH Closing Remarks 4:50PM Associate Professor of Medicine Brigham and Women’s Hospital / Harvard Medical School KEYNOTE SPEAKER Janine Austin Clayton, M.D.
    [Show full text]
  • Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1B
    RCD ESCS May 27, 2016 Protocol Title: Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) Protocol Number: 15-EI-0052 Date of This Submission/Version: May 27, 2016/ v5.0 Principal Investigator (PI) Bldg. 10, Wadih Zein, MD NEI/NIH 301-496-8118 [email protected] Rm. 10D45 Accountable Investigator Bldg. 10, Wadih Zein, MD NEI/NIH 301-496-8118 [email protected] Rm. 10D45 Associate Investigators (AI) Bldg. 10, Catherine Cukras, MD, PhD NEI/NIH 301-435-5061 [email protected] Rm. 10C438 Bldg. 10, Brett Jeffrey, PhD NEI/NIH 301-402-2391 [email protected] Rm. 10C442 Bldg. 10, Emily Chew, MD NEI/NIH 301-496-6583 [email protected] Rm. 3-2531 Bldg. 10, Amy Turriff, ScM NEI/NIH 301-402-4175 [email protected] Rm. 11C432B Bldg. 10, Henry Wiley, MD NEI/NIH 301-451-4260 [email protected] Rm. 10D45 Bldg. 6, Wai T. Wong, MD, PhD NEINIH 301-496-7566 [email protected] Rm. 217 Bldg. 10, Brian Brooks, MD, PhD NEI/NIH 301-451-2238 [email protected] Room 10B16 Bldg. 35, Kapil Bharti, PhD NEI/NIH 301-496-9661 [email protected] Rm. 2A-102 Bldg. 6, Anand Swaroop, PhD NEI/NIH 301-435-5754 [email protected] Rm. 338 Bldg. 10, Arvydas Maminishkis, PhD NEI/NIH 301-435-4902 [email protected] Rm. 10B04 Bldg. 31, Sheldon Miller, PhD NEI/NIH 301-496-3180 [email protected] Rm.
    [Show full text]
  • Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations for Fiscal Year 2014
    DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES APPROPRIATIONS FOR FISCAL YEAR 2014 WEDNESDAY, APRIL 2, 2014 U.S. SENATE, SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS, Washington, DC. The subcommittee met at 10 a.m., in room SD–192, Dirksen Sen- ate Office Building, Hon. Tom Harkin (chairman) presiding. Present: Senators Harkin, Durbin, Mikulski, Moran, Cochran, Shelby, and Kirk. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH STATEMENT OF FRANCIS S. COLLINS, M.D., PH.D., DIRECTOR ACCOMPANIED BY: ANTHONY S. FAUCI, M.D., DIRECTOR, NATIONAL INSTITUTE OF AL- LERGY AND INFECTIOUS DISEASES HAROLD E. VARMUS, M.D., DIRECTOR, NATIONAL CANCER INSTI- TUTE GARY H. GIBBONS, M.D., DIRECTOR, NATIONAL HEART, LUNG AND BLOOD INSTITUTE STORY C. LANDIS, PH.D., DIRECTOR, NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE CHRISTOPHER P. AUSTIN, M.D., DIRECTOR, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES OPENING STATEMENT OF SENATOR TOM HARKIN Senator HARKIN. The Appropriations Subcommittee on Labor, Health and Human Services, and Education, and Related Agencies will come to order. Good morning, everyone, and welcome. Sorry we are a little late. We had a vote at 10—that is all. Well, today will be my final Appropriations budget hearing for the NIH (National Institutes of Health) as the chair of this sub- committee. I took over this subcommittee from Senator Lawton Chiles in 1989. That is a long time ago it seems, a quarter century. I am so proud of all that we have done—all of us here—often on a bipartisan basis, to transform the National Institutes of Health into truly the jewel and the crown of biomedical research not only in the United States, but globally.
    [Show full text]
  • The National Institutes of Health (NIH): Background and Congressional Issues
    The National Institutes of Health (NIH): Background and Congressional Issues Updated April 19, 2019 Congressional Research Service https://crsreports.congress.gov R41705 SUMMARY R41705 The National Institutes of Health (NIH): April 19, 2019 Background and Congressional Issues Judith A. Johnson The National Institutes of Health (NIH), under the Department of Health and Human Specialist in Biomedical Services (HHS), is the primary federal agency charged with performing and supporting Policy biomedical and behavioral research. In FY2018, NIH used its over $34 billion budget to support more than 300,000 scientists and research personnel working at over 2,500 Kavya Sekar institutions across the United States and abroad, as well as to conduct biomedical and Analyst in Health Policy behavioral research and research training at its own facilities. The agency consists of the Office of the Director, in charge of overall policy and program coordination, and 27 institutes and centers, each of which focuses on particular diseases or research areas in human health. A broad range of research is funded through a highly competitive system of peer-reviewed grants and contracts. The Public Health Service Act (PHSA) provides the statutory basis for NIH programs, and funding levels are mostly provided through the annual appropriations process. In December 2016, Congress introduced major reforms and programs at the NIH through the 21st Century Cures Act (P.L. 114-255). Prior to 2016, the last time Congress addressed NIH with comprehensive legislation was in December 2006, when it passed the NIH Reform Act (P.L. 109-482). Congress also gives direction to NIH through appropriations report language, but usually not through budget line items or earmarks.
    [Show full text]
  • Living with Low Vision: How You Can Help
    Living With Low Vision: How you can help Mark E. Wilkinson, O.D. Neyal J. Ammary-Risch, M.P.H., MCHES Living With Low Vision: How you can help Mark E. Wilkinson, O.D. Neyal J. Ammary-Risch, M.P.H., MCHES University of Iowa Carver College of Medicine Director, National Eye Health Education Department of Ophthalmology and Visual Sciences Program Wynn Institute for Vision Research National Eye Institute, NIH Chair, Low Vision Subcommittee, National Eye Health Education Program National Eye Institute, NIH Overview We will define low vision and discuss: • Goals of vision rehabilitation • Who should have a low vision evaluation • Components of a structured examination • Core principles of vision rehabilitation • Resources Prevalence Data Number of low vision cases in the U.S. by race/ethnicity, 2010 Prevalence Data Projected number of low vision cases in the U.S., 2010–2050 Poll Question Some patients believe that low vision means having difficulty seeing objects below their waist. Poll Results Some patients believe that low vision means having difficulty seeing objects below their waist. Low Vision A visual impairment, not correctable by standard glasses, contact lenses, medicine, or surgery, that interferes with a person’s ability to perform everyday activities. Low Vision Rehabilitation • Is indicated if a visual impairment is serious enough to result in functional limitations or disability. • Is available regardless of level of visual acuity or field loss. • Is the only nonsurgical treatment for vision loss. The goal of low vision rehabilitation: Maximize daily functioning, increase independence, and improve quality of life. Enhancing Functional Abilities Accomplished by: • Prescribing optical and electronic devices • Educating patients • Teaching strategies that enhance functioning • Referring patients to other vision rehabilitation services: .
    [Show full text]
  • NEI 50 Years of Advance in Vision Research
    NEI: 50 years of advances in vision research 1 From the director The National Eye Institute was established by Congress in 1968 with an urgent mission: to protect and prolong vision. At the time, millions of Americans were going blind from common eye diseases and facing isolation and a diminished quality of life. Over the past 50 years, public investment in vision research has paid remarkable dividends. Research supported by NEI and conducted at medical centers, universities, and other institutions across the country and around the world—as well as in laboratory and clinical settings at the National Institutes of Health—has led to breakthrough discoveries and treatments. Today, many eye diseases can be treated with sight-saving therapies that stabilize or even reverse vision loss. NEI-supported advances have led to major improvements in the treatment of glaucoma, uveitis, retinopathy of prematurity, and childhood amblyopia. We have more effective treatments and preventive strategies for age-related macular degeneration and diabetic retinopathy. Recent successes in gene therapy and regenerative medicine suggest the future looks even brighter for both rare and common eye diseases. Basic research has revealed new insights about the structure and function of the eye, which also offers a unique window into the brain. In fact, much of what we know about how the brain works comes from studies of the retina. Decades of NEI research on retinal cells has led to fundamental discoveries about how one nerve cell communicates with another, how sets of cells organize into circuits that process different kinds of sensory information, and how neural tissue develops and organizes itself.
    [Show full text]
  • Diabetic Eye Disease Projected to Increase Among U.S. Population—Disease Will Reach 11 Million People by 2030
    Diabetic Eye Disease Projected To Increase Among U.S. Population Disease will reach 11 million people by 2030 Today, diabetes affects more than 29 million people in the United States or over 9 percent of the population. In addition, another 86 million American adults, more than one out of three individuals, have pre-diabetes, a condition that puts people at increased risk for diabetes. All people with diabetes, type 1 and type 2, are at risk for diabetic eye disease, a leading cause of vision loss and blindness. Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of the disease and includes cataract, diabetic retinopathy, and glaucoma. Diabetic retinopathy, the most common form of diabetic eye disease, is the leading cause of blindness in adults 20–74 years of age. According to the National Eye Institute (NEI), 7.7 million people age 40 and older have diabetic retinopathy, and this number is projected to increase to approximately 11 million people by 2030. “The longer a person has diabetes, the greater is his or her risk of developing diabetic eye disease,” said Paul A. Sieving, M.D., Ph.D., director of NEI. “If you have diabetes, be sure to have a comprehensive dilated eye exam at least once a year. Diabetic eye disease often has no early warning signs, but can be detected early and treated before vision loss occurs. Don’t wait until you notice an eye problem to have a dilated eye exam, because vision that is lost often cannot be restored.” While all people with diabetes can develop diabetic eye disease, African Americans, American Indians/Alaska Natives, and Hispanics/Latinos with diabetes are at higher risk of losing vision or going blind from it.
    [Show full text]
  • Development Evaluations in Uganda 2000-2018
    MAY 2021 CEDIL Syntheses Working Paper 1 Development evaluations in Uganda 2000–2018: A Country Evaluation Map Howard White, Timothy Lubanga, Francis Rathinam, Roland Bless Taremwa, Benjamin Kachero, Caroline Otike, Robert Apunyo, Zeba Siddiqui, Anagha Joshi, Ashrita Saran, and Ekwaro Obuku Development evaluations in Uganda 2000–2018: A Country Evaluation Map About CEDIL The Centre of Excellence for Development Impact and Learning (CEDIL) is an academic consortium supported by the UK government through UK Aid. The mission of the Centre is to test innovative methodologies in evaluation and evidence synthesis and promote evidence-informed development. CEDIL-supported projects fall into three programmes of work: evaluating complex interventions, enhancing evidence transferability, and increasing evidence use. CEDIL syntheses working papers The CEDIL Syntheses Working Paper series publishes innovative research syntheses of the impact of interventions in low- and middle-income countries in the form of evidence and gap maps, systematic reviews, meta-analyses and other synthesis products. About this working paper This paper is a report on a country evaluation map that makes existing development evaluations in Uganda accessible to users for supporting evidence-informed decision- making across government, development partners, and civil society. Suggested citation: White H., Lubanga T., Rathinam F., Taremwa R., Kachero B., Otike C., Apunyo R., Siddiqui Z., Joshi A., Saran A., and Obuku E. 2021. Development evaluations in Uganda 2000–2018: A Country Evaluation Map. CEDIL Syntheses Working Paper 1. Oxford: Centre of Excellence for Development Impact and Learning (CEDIL). Available at: https://doi.org/10.51744/CSWP1 Cover design: PhilDoesDesign Cover picture credit: "Hands Up" by SimonWhitaker is licensed under CC BY-NC 2.0 Copyright: © 2021 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]